Neoolife is developing tissue-engineered heart valves and cardiovascular patches using its Double Component Deposition platform. Licensed from the University of Pittsburgh and Fondazione RiMED, the technology supports both resorbable and permanent materials, including the non-resorbable OneValveTric transcatheter tricuspid valve. [1] [2]
The company’s preclinical programs aim to improve the durability and biological performance of cardiovascular implants. Cofounders Antonio D’Amore, Vinay Badhwar, Garrett Coyan, Giuseppe D’Ancona, David Kokot and William Wagner bring together clinical, engineering and commercialization expertise. A multimillion-dollar medical-device development agreement announced in 2024 supports its work. [3] [4]